LAKEWOOD, Colo., Oct. 03, 2017 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2017, to shareholders of record at the close of business on November 30, 2017.
About Mesa Laboratories, Inc.
Mesa is a global technology innovator committed to solving some of the most critical quality control and analytical challenges in the pharmaceutical, healthcare, industrial safety, environmental and food & beverage industries. Through Mesa’s four divisions: Biological Indicators, Instruments, Cold Chain Monitoring and Cold Chain Packaging we help our customers ensure product integrity, increase patient and worker safety, and design innovative solutions that improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes "forward-looking statements." Generally, the words "believe," “estimate,” "expect," "project," “anticipate,” “intend,” "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. These risks and uncertainties include, but are not limited to, those described in our Annual Report on Form 10-K for the year ended March 31, 2017, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.
CONTACT: Gary Owens; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc., +1-303-987-8000
For more information about the Company, please visit its website at www.mesalabs.com.


Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 



